RBC Capital reiterates Wave Life Sciences stock rating on obesity data

try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Retired U.S. admiral warns Iran war could last longer than expected Oil prices tick down, set for weekly losses on Middle East de-escalation hopes Trump extends pause to Iran power plant strikes - what’s moving markets Iran conflict latest: Trump pauses Iran energy plant strikes by 10 days (South Africa Philippines Nigeria) RBC Capital reiterates Wave Life Sciences stock rating on obesity data By Analyst Ratings Published 03/27/2026, 05:54 AM RBC Capital reiterates Wave Life Sciences stock rating on obesity data 0 WVE -49.59% Investing.com - RBC Capital reiterated an Outperform rating and $27.00 price target on Wave Life Sciences (NASDAQ:WVE) following updated data from the company’s INHBE obesity program. The optimistic outlook comes despite the stock trading at $6.20, down 47% over the past week, though analysts maintain a Strong Buy consensus with price targets ranging from $11 to $52. Wave Life Sciences reported results showing patients on the 240 mg dose experienced 0.3% and 0.9% reductions in body weight at three and six months, along with 8% and 14% reductions in visceral fats. The 240 mg dose also showed 5% reduction in total fat and 2% increase in lean mass at both time points. At the 400 mg dose, the company reported 5% reduction in visceral fats and 0.7% reduction in total fats at three months. Wave Life Sciences noted that patients enrolled had baseline BMI in the low 30s, materially lower than patients in most Phase II/III obesity trials who typically have BMI in the high 30s.According to InvestingPro analysis, the stock appears undervalued at current levels, with the company maintaining a strong balance sheet including more cash than debt. For deeper insights, investors can access Wave Life Sciences’ comprehensive Pro Research Report, one of 1,400+ available reports transforming complex data into actionable intelligence. The drug was generally well tolerated with all study drug-related adverse e...